Food and Drug Administration

Biological Response Modifiers Advisory Committee

October 25, 2001


Lentiviral Vectors, Gene Therapy, Dr. Inder Verma, Salk Institute for Biological Studies   ppt   htm

Lentiviral Vectors: Safety Issues, Daniel Takefman, PhD, FDA   ppt   htm

Safety Features in the Design, Manufacture and Clinical Monitoring of Lentivectors for the Treatment of Parkinson's Disease, Prostate Cancer and Aids, Susan M Kingsman, Oxford BioMedica (UK) Ltd.   ppt   htm

Predicting Lentiviral Vector Safety In Vivo, Dr. John Kappes, University of Alabama at Birmingham   ppt   htm